Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MMP14 (matrix metallopeptidase 14 (membrane-inserted))

Written2010-10Cem Kuscu, Nikki Evensen, Jian Cao
Division of Cancer Prevention, Stony Brook University, Stony Brook, New York 11794, USA

(Note : for Links provided by Atlas : click)

Identity

Alias (NCBI)MMP-X1
MT1-MMP
MTMMP1
HGNC (Hugo) MMP14
HGNC Alias symbMT1-MMP
HGNC Alias namemembrane type 1 metalloprotease
 membrane type 1-matrix metalloproteinase
HGNC Previous namematrix metalloproteinase 14 (membrane-inserted)
 matrix metallopeptidase 14 (membrane-inserted)
LocusID (NCBI) 4323
Atlas_Id 41391
Location 14q11.2  [Link to chromosome band 14q11]
Location_base_pair Starts at 22836585 and ends at 22847758 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping MMP14.png]
Fusion genes
(updated 2017)		Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ETNK2 (1q32.1) / MMP14 (14q11.2)MMP14 (14q11.2) / H19 (11p15.5)MMP14 (14q11.2) / MED23 (6q23.2)
MMP14 (14q11.2) / MMP14 (14q11.2)PDXDC1 (16p13.11) / MMP14 (14q11.2)SFTPA2 (10q22.3) / MMP14 (14q11.2)

DNA/RNA

 
Description MMP14 spans 11009 bp on chromosome 14 in the region of q11.2. It consists of 10 exons.
Transcription The human MMP-14 (MT1-MMP) transcript has been determined to be 3558 bp in length before splicing and 1749 bp after splicing. The start codon (ATG) of MMP-14 gene exists in the first exon and the stop codon (TGA) is present in the last and longest exon of the transcribed product of MMP-14. No TATA box, which controls the expression of 30% of all genes found in the human genome, is found in the proximal region in the MMP-14 promoter. In the promoter region, Egr-1 has been reported to be one of the most important transcription factors regulating the expression of MMP-14. MMP-14 expression is also regulated by other transcription factors, including AP-4, NF-kB, c-ETS1 and p53. However, some common transcription factors, such as AP-1, AP-2 and TGF-alpha, which play major roles in the regulation of other MMPs do not have binding sites within the promoter of MMP-14. Besides these common transcription factors, MMP-14 expression is also regulated by hypoxia inducible factor 2a (HIF-2alpha) under hypoxic conditions. Two HBSs (HIF binding site) have been identified in the proximal promoter region, the one around -125 bp relative to the transcription start site is shown to affect MMP-14 transcription. Some growth factors and cytokines, e.g IL1B, EGF, TNFalpha, bFGF, GM-CSF, SF/HGF, and TGF-beta have also been reported to induce the expression of MMP-14.
Two functional SNPs in the MMP-14 promoter have been found in focal-segmental glomerulosclerosis (FSGS) disease. -378 T/C and -364 G/T alterations cause a reduction in the expression of MMP-14 and correlate with significant risk reduction of FSGS. Epigenetic regulation is also involved in the regulation of MMP-14 expression. Hypermethylation of the CpG100 island, which spans a region from the proximal promoter to the 1st intron of MMP-14, and trimethylation of Histone H3 lysine-27 (known as a repressive marker) are determined as epigenetic controls causing the transcriptional silencing of MMP-14.
Pseudogene No pseudogenes have been identified.

Protein

 
  Schematic representation of the domain structures of MMP-14 (domains are not scaled).
Description Matrix metalloproteinases (MMPs) compose one of the metzincins super family also known as zinc endopeptidases. Highly conserved motif of this family contains three histidines that bind zinc ion in the catalytic site of the protein and conserved methionine. Besides the secreted MMPs of the MMP family, six membrane type-MMPs have been identified so far, all with similar domain compositions. The best characterized MT-MMP is MMP-14 or MT1-MMP, which contains seven domains from N-terminus to C-terminus: a signal peptide leading MMP-14 into the secretory pathway; a propeptide domain maintaining MMP in a latent form; a catalytic domain responsible for enzymatic activity; a hinge region maintaining proper conformation; a hemopexin domain required for substrate reorganization; a transmembrane domain anchoring MMP into the plasma membrane; and a cytoplasmic domain required for endocytosis. MT-1, MT2-, MT3- and MT5-MMPs all contain seven similar domains, whereas MT4- and MT6-MMPs lack the transmembrane and cytoplasmic domains. Both MT4- and MT6-MMPs are linked to the cell surface through GPI-anchorage. There is a furin consensus sequence (Arg108-Arg109-Lys110-Arg111) between MMP-14 propeptide and catalytic domains. Furin has been reported to be responsible for MMP-14 activation. However, the activation mechanism of MMP-14 is still under debate. The hemopexin-like domain of MMP-14 is the largest domain, and it provides a suitable flat surface for the protein-protein interactions with the existence of four bladed beta-propeller structures.
Expression MMP-14 is widely expressed in human tissues. Its expression has been proven in the adult human intestine, kidney, lung, ovary, placenta, prostate, and spleen. Increase in its expression level has also been observed in the wound healing area. A Mouse embryogenesis study provides evidence for the expression of MMP-14 mainly in the muscle cells, fibroblast, chondrocytes, and neural cells. MMP-14 is upregulated in most human cancers. Both cancer and stromal cells have been reported to be upregulated in tumor tissues.
Localisation Plasma Membrane (single-pass type I membrane protein). MMP-14 contains a 24 amino acid hydrophobic motif at the C-terminus which is responsible for plasma membrane localization of MMP-14.
Function MMP-14 plays an important role in remodelling of extracellular matrix (ECM) and enhancing cell migration. Besides the role of MMP-14 in these pathophysiological processes, it also plays an important physiological role during development. Studies performed with MMP-14 null mice have shown the importance of its function during embryogenesis as the lack of MMP-14 caused craniofacial dysmorphism, arthritis, osteopenia, dwarfism, fibrosis of soft tissues and premature death. In the adult life, MMP-14 is also required for the wound healing process. All of these functions are related to MMP-14's cleavage or activation of the protein within its substrate profile, which includes proteins in ECM, pro-MMPs, cell-adhesion molecules, cytokines, growth factors and receptors on the cell membrane. Recent studies have also demonstrated the activation of signal transduction pathways via the cytoplasmic tail of MMP-14 important for the invasion process. Functions of MMP-14 can be summarized under the categories of activation of proMMMPs; degradation of ECM; shedding of cell surface molecules; cleavage of cytokines and growth factors; and activation of ERK cascade.

I-) Activation of proMMPs and degradation of ECM
Pro-MMP2 was the first identified substrate of MMP-14 and the trimolecular complex consisting of MMP-14 and proMMP2-TIMP2 has been investigated very well for many years. TIMP2 (tissue inhibitor of metalloproteinases-2) is actually the inhibitor of the MMPs. However, low concentrations of TIMP-2 aids in the activation of proMMP-2 by MMP-14 within this complex by binding to the catalytic domain of MMP-14 and the C-terminal domain of pro-MMP2. Following the formation of the triplex, a second MMP-14, which is free of TIMP-2, forms a dimer with the pre-existing MMP-14 on the cell membrane and cleaves the latent pro-MMP2 to produce active MMP2. Active MMP-2 can then participate in other events such as the degradation of collagen type-IV, a major protein component of the basement membrane, which is not cleaved by MMP-14 itself. Another substrate of MMP-14 within the MMP family is the pro-MMP-13, which also functions as a collagenase in the surrounding tissue after its activation.
Besides activation of MMPs, especially pro-MMP-2, MMP-14 cleaves many proteins in the ECM and changes the composition of the matrix. Type I-Type II-Type III collagen, gelatin, fibronectin, laminin-1 and -5, fibrin and proteoglycans are the major direct targets of MMP-14 in the extracellular environment. Out of these substrates, collagen makes up a significant portion of the ECM and acts as a barrier for migratory cells. Within the collagenases, which includes MMP-1, MMP-2, MMP-8, MMP-13, only MMP-14 can stimulate invasion into collagen by epithelial cells, fibroblasts, and cancer cells. MMP-14 concentrates in the protrusions of the cells, called lamellipodia in normal cells and invadopodia in cancer cells, to induce a significant increase in cell migration and invasion by degrading components of the ECM and making a path in through the surrounding tissue. In this aspect, MMP-14 should be bound to the plasma membrane in vivo, as membrane-bound MMP-14 has been demonstrated to be more proteolytically active than the soluble recombinant MMP-14.

II-) Shedding of cell surface molecules
Studies underlying the mechanism of the constitutive shedding of CD44 from the human melanoma cell surface implicated the necessity of MMP-14 with the presence of ADAM-10 for this process. Especially in the hyaluronan based matrix, cleavage of CD44 at the stem region by MMP-14 sheds these molecules from the cell surface and concurrently promotes the migration of the cells from the leading edge. Another cell adhesion molecule, E-cadherin, is also cleaved by MMP-14 to disrupt contact between cells. In the ischemia-induced ARF (acute renal failure), MMP-14 expression is required for the disruption of the cadherin/catenin complex. Syndecan-1 is another cell surface molecule which is cleaved by MMP-14.

III-) Cleavage of cytokines and growth factors
MMP-14 indirectly plays a major role in cleavage of the cytokines and growth factors by activating pro-MMP-2 and pro-MMP13. It also makes direct contact with several chemokines and growth factors including; the neutrophil chemokine IL-8, secretory leukocyte protease inhibitor, pro-tumor necrosis factor, death receptor-6, and connective tissue growth factor.

IV-) Activation of ERK cascade by the cytoplasmic tail of MMP-14
In several studies, overexpression of MMP-14 has been reported to activate the ERK cascade. It is not yet clear how MMP-14 activates ERK signalling, but overexpression of the cytoplasmic-deleted form of MMP-14 has been shown to eradicate ERK activation. Within the cytoplasmic tail, the 573YCQR576 motif has been suggested to be involved in ERK activation. In addition to ERK activation, the role of MMP-14 in the p38 and JNK pathway has also been investigated.

V-) Inhibition of MMP-14 function
Function of MMP-14 can be abolished either by TIMPs (Tissue Inhibitor of MetalloProteinases) or proteolytic degradation. TIMP-2, -3 and -4 but not TIMP-1 specifically inactivates the functions of MMP-14. Besides TIMPs, RECK and N-Tes can also block the activity of MMP-14 in a similar manner. For the proteolytic cleavage of MMP-14, membrane bound MMP-14 should be internalized by the clathrin-dependent and caveolae-dependent pathways. There is an AP-2 binding site in the cytoplasmic domain of MMP-14, 571LLY573 which is required for the incorporation of MMP-14 into clathrin-coated vesicles. The palmitoylation of the C574 right after the AP-2 binding site has also been demonstrated to be an essential modification for the internalization of MMP-14.

Homology All MT-MMPs have shown a 40-50% identity according to their amino acid sequence. In the phylogenetic tree, MMP-14 shares the highest similarity rate with MT2-MMP (MMP-15).

Implicated in

Note
  
Entity Various cancers
Note Degradation of the ECM by MMP-14 has been linked to proliferation, invasion and metastasis of cancer cells in most cancer types. The expression level of MMP-14 has also been correlated with invasiveness in many cancer cell lines, especially for breast carcinoma. Increase in the MMP-14 expression level has also been observed in a variety of human tumors, including lung, gastric, breast, colon, liver, pancreatic, thyroid, head and neck, ovarian, prostate, bladder, cervical and brain tumors. Genetic alterations, such as gene amplification or activating mutations, have not been observed for MMP-14 in these cancer types, therefore up regulation of MMP-14 has been linked to the transcriptional changes during tumor formation. Immunohistochemical and in-situ hybridization analysis have demonstrated the presence of MMP-14 in both tumor cells and stromal cells. Interestingly, most of the MMP-14 expression is produced by the stromal cells rather than the cancer cells in many tumor types, including breast and lung tumors. The possible explanation for this observation is the production of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) by the cancer cells on their cell surface. EMMPRIN stimulates the surrounding stromal cells to produce MMPs, including MMP-14. However, in some human cancers, including thyroid, brain, and head and neck cancer, a majority of the MMP-14 expression has been shown to be produced by the cancer cells rather than surrounding stromal cells. Another major role of the MMP-14 expression for tumor formation is the upregulation of VEGF production. VEGF is the key molecule for the vascularisation of tumor cells and angiogenesis. For the VEGF gene transcription, C-terminal of MMP-14 in the cytoplasmic tail has a structural region composed of 574CQRSLLDKV582.
  
  
Entity Atherosclerosis
Note In the numerous stages of atherosclerosis, pro-inflammatory molecules such IL-1a, TNF-a and oxidized-LDL trigger the smooth muscle cells (SMC) and macrophages to increase their levels of MMP-14. Higher expression of MMP-14 activates its downstream molecule, pro-MMP-2, and then both MMP-14 and MMP-2 contribute to the abnormal matrix turnover, leading to the atherosclerotic plaques in the walls of arteries.
  
  
Entity Rheumatoid disease
Note It has been reported that fibroblasts, macrophages, and osteoclast-like cells in both the lining and sublinig layers of the rheumatoid synovial tissue have higher expression of MMP-14 and MT3-MMP. Effects of MMP-14 have been implicated in the destruction of tissue seen in arthritis. Successful suppression of the joint destruction has also been observed after treatment with one of the MMP-14 inhibitors, called FR217840.
  
  
Entity Neurologic disease
Note Neurons and astrocytes have been known to express MMPs and remodel the ECM after nerve injury in the body. In the case of amyotrophic lateral sclerosis, MMP-14 expression has been found to be increased in the astrocytes of affected tissues of the mouse central nervous system.
  
  
Entity Lung disease
Note Vascular endothelial cells and bronchial epithelial cells of the lung were injured by the high volume ventilation in the ventilator-induced lung (VIL) rat model. In the injured cells of the VIL, an increase in the MMP-14 expression has been reported. Prinomastat, an MMP-14 inhibitor, treatment of the VIL rat has also been shown to abolish the injury.
  
  
Entity Kidney disease
Note Data suggest that the development of crescentic glomerulonephritis, a kidney disease characterized by inflammation of the glomeruli or small blood vessels, triggered by the expression of MMP-14 in macrophages. In this disease, MMP-14 activates proMMP-2, and then they both contribute to the pathological degradation of the ECM.
  

Bibliography

MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.
Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, Seiki M, Stamp GW.
Hum Pathol. 1998 Feb;29(2):155-65.
PMID 9490275
 
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, Voelcker V, Sleeman JP, Simon JC.
J Invest Dermatol. 2009 Jun;129(6):1471-82. Epub 2008 Oct 30.
PMID 18971959
 
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer.
Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S.
J Biol Chem. 2008 Mar 7;283(10):6232-40. Epub 2008 Jan 3.
PMID 18174174
 
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration.
Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou WF, Zucker S.
J Biol Chem. 2004 Apr 2;279(14):14129-39. Epub 2004 Jan 16.
PMID 14729674
 
Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase.
Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C.
J Biol Chem. 2005 Mar 25;280(12):10974-80. Epub 2005 Jan 6.
PMID 15637056
 
Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.
Chernov AV, Sounni NE, Remacle AG, Strongin AY.
J Biol Chem. 2009 May 8;284(19):12727-34. Epub 2009 Mar 13.
PMID 19286653
 
Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14).
Covington MD, Burghardt RC, Parrish AR.
Am J Physiol Renal Physiol. 2006 Jan;290(1):F43-51. Epub 2005 Aug 2.
PMID 16077081
 
Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340).
Foda HD, Rollo EE, Drews M, Conner C, Appelt K, Shalinsky DR, Zucker S.
Am J Respir Cell Mol Biol. 2001 Dec;25(6):717-24.
PMID 11726397
 
Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration.
Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM.
J Cell Sci. 2001 Aug;114(Pt 16):2967-76.
PMID 11686300
 
Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP).
Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Beliveau R.
FEBS Lett. 2001 Oct 26;507(2):231-6.
PMID 11684104
 
Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium.
Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA.
J Biol Chem. 1999 Aug 6;274(32):22679-85.
PMID 10428849
 
Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis.
Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y.
J Pathol. 2000 Jul;191(3):299-305.
PMID 10878552
 
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H.
Cell. 1999 Oct 1;99(1):81-92.
PMID 10520996
 
Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase.
Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M.
J Biol Chem. 1999 Nov 26;274(48):34260-6.
PMID 10567400
 
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis.
Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, Pei D.
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13693-8. Epub 2001 Nov 6.
PMID 11698655
 
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.
Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G.
J Biol Chem. 1996 Jul 19;271(29):17124-31.
PMID 8663255
 
Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP.
Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M.
FEBS Lett. 2000 Sep 1;480(2-3):142-6.
PMID 11034316
 
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.
Lee MH, Atkinson S, Rapti M, Handsley M, Curry V, Edwards D, Murphy G.
Cancer Lett. 2010 Apr 1;290(1):114-22. Epub 2009 Oct 7.
PMID 19815335
 
Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs.
Munkert A, Helmchen U, Kemper MJ, Bubenheim M, Stahl RA, Harendza S.
Nephrol Dial Transplant. 2009 Mar;24(3):735-42. Epub 2008 Oct 16.
PMID 18927121
 
Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer.
Overall CM, Dean RA.
Cancer Metastasis Rev. 2006 Mar;25(1):69-75. (REVIEW)
PMID 16680573
 
Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.
Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, Gay S.
Arthritis Rheum. 2000 Jun;43(6):1226-32.
PMID 10857781
 
Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP.
Pei D.
J Biol Chem. 1999 Mar 26;274(13):8925-32.
PMID 10085137
 
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL, Lohi J, Brinckerhoff CE.
Oncogene. 2005 Feb 3;24(6):1043-52.
PMID 15592504
 
Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia.
Poincloux R, Lizarraga F, Chavrier P.
J Cell Sci. 2009 Sep 1;122(Pt 17):3015-24. (REVIEW)
PMID 19692588
 
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase.
Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P.
J Biol Chem. 1999 Apr 23;274(17):11924-9.
PMID 10207013
 
Elevated expression of membrane type 1 metalloproteinase (MT1-MMP) in reactive astrocytes following neurodegeneration in mouse central nervous system.
Rathke-Hartlieb S, Budde P, Ewert S, Schlomann U, Staege MS, Jockusch H, Bartsch JW, Frey J.
FEBS Lett. 2000 Sep 22;481(3):227-34.
PMID 11007969
 
Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.
Stamenkovic I, Yu Q.
J Invest Dermatol. 2009 Jun;129(6):1321-4.
PMID 19434087
 
Structural features of a superfamily of zinc-endopeptidases: the metzincins.
Stocker W, Bode W.
Curr Opin Struct Biol. 1995 Jun;5(3):383-90. (REVIEW)
PMID 7583637
 
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease.
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI.
J Biol Chem. 1995 Mar 10;270(10):5331-8.
PMID 7890645
 
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates.
Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM.
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6917-22. Epub 2004 Apr 26.
PMID 15118097
 
Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells.
Tomita T, Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Yamashita T, Ishiguro R, Kanzaki J, Kameyama K, Otani Y.
Cancer Lett. 2000 Aug 1;156(1):83-91.
PMID 10840163
 
Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.
Velasco G, Cal S, Merlos-Suarez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, Lopez-Otin C.
Cancer Res. 2000 Feb 15;60(4):877-82.
PMID 10706098
 
cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment.
Will H, Hinzmann B.
Eur J Biochem. 1995 Aug 1;231(3):602-8.
PMID 7649159
 
Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium.
Yun S, Dardik A, Haga M, Yamashita A, Yamaguchi S, Koh Y, Madri JA, Sumpio BE.
J Biol Chem. 2002 Sep 20;277(38):34808-14. Epub 2002 Jul 1.
PMID 12093818
 
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.
Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7.
PMID 10737763
 
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J.
Int J Cancer. 1998 Mar 2;75(5):780-6.
PMID 9495249
 

Citation

This paper should be referenced as such :
Kuscu, C ; Evensen, N ; Cao, J
MMP14 (matrix metallopeptidase 14 (membrane-inserted))
Atlas Genet Cytogenet Oncol Haematol. 2011;15(6):502-506.
Free journal version : [ pdf ]   [ DOI ]

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 2 ]
  Lung: Translocations in Adenocarcinoma
t(14;16)(q11;p13) PDXDC1/MMP14

External links

Nomenclature
HGNC (Hugo)MMP14   7160
Cards
AtlasMMP14ID41391ch14q11
Entrez_Gene (NCBI)MMP14    matrix metallopeptidase 14
AliasesMMP-14; MMP-X1; MT-MMP; MT-MMP; 
MT1-MMP; MT1MMP; MTMMP1; WNCHRS
GeneCards (Weizmann)MMP14
Ensembl hg19 (Hinxton)ENSG00000157227 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000157227 [Gene_View]  ENSG00000157227 [Sequence]  chr14:22836585-22847758 [Contig_View]  MMP14 [Vega]
ICGC DataPortalENSG00000157227
TCGA cBioPortalMMP14
AceView (NCBI)MMP14
Genatlas (Paris)MMP14
SOURCE (Princeton)MMP14
Genetics Home Reference (NIH)MMP14
Genomic and cartography
GoldenPath hg38 (UCSC)MMP14  -     chr14:22836585-22847758 +  14q11.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MMP14  -     14q11.2   [Description]    (hg19-Feb_2009)
GoldenPathMMP14 - 14q11.2 [CytoView hg19]  MMP14 - 14q11.2 [CytoView hg38]
ImmunoBaseENSG00000157227
genome Data Viewer NCBIMMP14 [Mapview hg19]  
OMIM277950   600754   
Gene and transcription
Genbank (Entrez)AK291325 AK312657 BC039581 BC064803 BQ009340
RefSeq transcript (Entrez)NM_004995
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)MMP14
Alternative Splicing GalleryENSG00000157227
Gene ExpressionMMP14 [ NCBI-GEO ]   MMP14 [ EBI - ARRAY_EXPRESS ]   MMP14 [ SEEK ]   MMP14 [ MEM ]
Gene Expression Viewer (FireBrowse)MMP14 [ Firebrowse - Broad ]
GenevisibleExpression of MMP14 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4323
GTEX Portal (Tissue expression)MMP14
Human Protein AtlasENSG00000157227-MMP14 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP50281   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP50281  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP50281
Splice isoforms : SwissVarP50281
Catalytic activity : Enzyme3.4.24.80 [ Enzyme-Expasy ]   3.4.24.803.4.24.80 [ IntEnz-EBI ]   3.4.24.80 [ BRENDA ]   3.4.24.80 [ KEGG ]   [ MEROPS ]
PhosPhoSitePlusP50281
Domaine pattern : Prosite (Expaxy)CYSTEINE_SWITCH (PS00546)    HEMOPEXIN (PS00024)    HEMOPEXIN_2 (PS51642)    ZINC_PROTEASE (PS00142)   
Domains : Interpro (EBI)Hemopexin-like_dom    Hemopexin-like_dom_sf    Hemopexin-like_repeat    Hemopexin_CS    M10A_MMP    MetalloPept_cat_dom_sf    Pept_M10_metallopeptidase    Pept_M10A    Pept_M10A_metallopeptidase_C    Pept_M10A_Zn_BS    Peptidase_Metallo    Peptidoglycan-bd-like    PGBD-like_sf    PGBDSf   
Domain families : Pfam (Sanger)DUF3377 (PF11857)    Hemopexin (PF00045)    Peptidase_M10 (PF00413)    PG_binding_1 (PF01471)   
Domain families : Pfam (NCBI)pfam11857    pfam00045    pfam00413    pfam01471   
Domain families : Smart (EMBL)HX (SM00120)  ZnMc (SM00235)  
Conserved Domain (NCBI)MMP14
Blocks (Seattle)MMP14
PDB (RSDB)1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
PDB Europe1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
PDB (PDBSum)1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
PDB (IMB)1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
Structural Biology KnowledgeBase1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
SCOP (Structural Classification of Proteins)1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
CATH (Classification of proteins structures)1BQQ    1BUV    2MQS    3C7X    3MA2    3X23    4P3C    4P3D    4QXU    5H0U    6CLZ    6CM1   
SuperfamilyP50281
Human Protein Atlas [tissue]ENSG00000157227-MMP14 [tissue]
Peptide AtlasP50281
HPRD02856
IPIIPI00218398   IPI01022293   IPI01022788   
Protein Interaction databases
DIP (DOE-UCLA)P50281
IntAct (EBI)P50281
BioGRIDMMP14
STRING (EMBL)MMP14
ZODIACMMP14
Ontologies - Pathways
QuickGOP50281
Ontology : AmiGOskeletal system development  angiogenesis  ovarian follicle development  response to hypoxia  endothelial cell proliferation  endochondral ossification  endopeptidase activity  metalloendopeptidase activity  metalloendopeptidase activity  integrin binding  protein binding  extracellular space  nucleus  cytoplasm  Golgi lumen  cytosol  plasma membrane  plasma membrane  integral component of plasma membrane  focal adhesion  proteolysis  proteolysis  response to oxidative stress  zinc ion binding  male gonad development  response to mechanical stimulus  response to hormone  positive regulation of myotube differentiation  positive regulation of protein processing  response to organic cyclic compound  protein processing  extracellular matrix disassembly  extracellular matrix organization  positive regulation of cell growth  lung development  positive regulation of cell migration  collagen catabolic process  collagen catabolic process  extracellular matrix  cytoplasmic vesicle  zymogen activation  zymogen activation  endodermal cell differentiation  chondrocyte proliferation  melanosome  astrocyte cell migration  response to estrogen  macropinosome  intermediate filament cytoskeleton  positive regulation of B cell differentiation  negative regulation of Notch signaling pathway  embryonic cranial skeleton morphogenesis  branching morphogenesis of an epithelial tube  tissue remodeling  cell motility  negative regulation of focal adhesion assembly  head development  metalloaminopeptidase activity  metalloaminopeptidase activity  craniofacial suture morphogenesis  regulation of protein localization to plasma membrane  positive regulation of macrophage migration  response to odorant  
Ontology : EGO-EBIskeletal system development  angiogenesis  ovarian follicle development  response to hypoxia  endothelial cell proliferation  endochondral ossification  endopeptidase activity  metalloendopeptidase activity  metalloendopeptidase activity  integrin binding  protein binding  extracellular space  nucleus  cytoplasm  Golgi lumen  cytosol  plasma membrane  plasma membrane  integral component of plasma membrane  focal adhesion  proteolysis  proteolysis  response to oxidative stress  zinc ion binding  male gonad development  response to mechanical stimulus  response to hormone  positive regulation of myotube differentiation  positive regulation of protein processing  response to organic cyclic compound  protein processing  extracellular matrix disassembly  extracellular matrix organization  positive regulation of cell growth  lung development  positive regulation of cell migration  collagen catabolic process  collagen catabolic process  extracellular matrix  cytoplasmic vesicle  zymogen activation  zymogen activation  endodermal cell differentiation  chondrocyte proliferation  melanosome  astrocyte cell migration  response to estrogen  macropinosome  intermediate filament cytoskeleton  positive regulation of B cell differentiation  negative regulation of Notch signaling pathway  embryonic cranial skeleton morphogenesis  branching morphogenesis of an epithelial tube  tissue remodeling  cell motility  negative regulation of focal adhesion assembly  head development  metalloaminopeptidase activity  metalloaminopeptidase activity  craniofacial suture morphogenesis  regulation of protein localization to plasma membrane  positive regulation of macrophage migration  response to odorant  
Pathways : KEGGTNF signaling pathway    GnRH signaling pathway   
REACTOMEP50281 [protein]
REACTOME PathwaysR-HSA-1592389 [pathway]   
NDEx NetworkMMP14
Atlas of Cancer Signalling NetworkMMP14
Wikipedia pathwaysMMP14
Orthology - Evolution
OrthoDB4323
GeneTree (enSembl)ENSG00000157227
Phylogenetic Trees/Animal Genes : TreeFamMMP14
HOGENOMP50281
Homologs : HomoloGeneMMP14
Homology/Alignments : Family Browser (UCSC)MMP14
Gene fusions - Rearrangements
Fusion : MitelmanMMP14/H19 [14q11.2/11p15.5]  
Fusion : MitelmanPDXDC1/MMP14 [16p13.11/14q11.2]  
Fusion PortalPDXDC1 16p13.11 MMP14 14q11.2 PRAD
Fusion : Fusion_HubATP2A2--MMP14    COL1A1--MMP14    COL1A2--MMP14    COL3A1--MMP14    EPN1--MMP14    ETNK2--MMP14    FGFR3--MMP14    MAP2K3--MMP14    MMP14--ACSF2    MMP14--CCT5    MMP14--CRYAB    MMP14--LAMA2    MMP14--MED23    MMP14--MMP14    MMP14--RBM23   
MMP14--SMTN    MMP14--SPARC    MMP14--WDR83OS    PDXDC1--MMP14    SFTPA2--MMP14    TBP--MMP14   
Fusion : QuiverMMP14
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMMP14 [hg38]
dbVarMMP14
ClinVarMMP14
MonarchMMP14
1000_GenomesMMP14 
Exome Variant ServerMMP14
GNOMAD BrowserENSG00000157227
Varsome BrowserMMP14
Genomic Variants (DGV)MMP14 [DGVbeta]
DECIPHERMMP14 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisMMP14 
Mutations
ICGC Data PortalMMP14 
TCGA Data PortalMMP14 
Broad Tumor PortalMMP14
OASIS PortalMMP14 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMMP14  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DMMP14
Mutations and Diseases : HGMDMMP14
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch MMP14
DgiDB (Drug Gene Interaction Database)MMP14
DoCM (Curated mutations)MMP14 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)MMP14 (select a term)
intoGenMMP14
NCG6 (London) select MMP14
Cancer3DMMP14(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM277950    600754   
Orphanet3042    11654   
DisGeNETMMP14
MedgenMMP14
Genetic Testing Registry MMP14
NextProtP50281 [Medical]
GENETestsMMP14
Target ValidationMMP14
Huge Navigator MMP14 [HugePedia]
ClinGenMMP14
Clinical trials, drugs, therapy
MyCancerGenomeMMP14
Protein Interactions : CTD
Pharm GKB GenePA30872
PharosP50281
Clinical trialMMP14
Miscellaneous
canSAR (ICR)MMP14 (select the gene name)
HarmonizomeMMP14
DataMed IndexMMP14
Probes
Litterature
PubMed499 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
EVEXMMP14
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Feb 19 17:55:18 CET 2021
Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.